Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Neoadjuvant Intense ADT for High Risk Prostate Cancer

ABSTRACT: Neoadjuvant Intense ADT for High Risk Prostate Cancer

PROVIDER: PRJNA591229 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Neoadjuvant Intense ADT for High Risk Prostate Cancer

Project description:Neoadjuvant Intense ADT for High Risk Prostate Cancer

| PRJNA591228 | ENA

Neoadjuvant Intense ADT for High Risk Prostate Cancer: Baseline Analysis

Project description:Neoadjuvant Intense ADT for High Risk Prostate Cancer: Baseline Analysis

| PRJNA639568 | ENA

Neoadjuvant Intense ADT for High Risk Prostate Cancer: Baseline Analysis

Project description:The purpose of this study was to develop better ways of detecting prostate cancer before and after pre-operative treatment, and to test the feasibility of multi parametric magnetic resonance imaging (mpMRI) for the localization and detection of focal prostate cancer both before and after pre-operative treatment with ADT and enzalutamide. In this study, patients with intermediate and high risk prostate cancer received six months of neoadjuvant intense androgen deprivation therapy prior to radical prostatectomy. Biopsies were acquired prior to treatment. Tissue from biopsy and radical prostatectomy were subjected to sequencing and analysis for determination of features associated with response or resistance to treatment.

2025-08-21 | GSE152516 | GEO

Immune signature driven by ADT-induced immune microenvironment remodeling in prostate cancer is correlated with recurrence-free survival and immune infiltration

Project description:Androgen deprivation therapy (ADT) is a cornerstone treatment for locally advanced or metastatic prostate cancer (PCa). However, its potential effects on the tumor immune microenvironment (TIM) of PCa patients and the underlying mechanism remain largely unclear.We used RNA sequencing to reveal the effects of ADT on the PCa TIM at the transcriptome level. RNA sequencing was performed on 6 paired pre-ADT biopsy and post-ADT PCa lesions and 5 paired paracancerous benign tissues from patients receiving neoadjuvant ADT with locally advanced PCa.

2020-09-23 | GSE150368 | GEO

Bulk RNA-seq analysis of prostate tissues treated with neoadjuvant ADT plus enzalutamide

Project description:Bulk RNA-seq analysis of prostate tissues treated with neoadjuvant ADT plus enzalutamide

| PRJNA759198 | ENA

Bulk Affymetrix Exon array analysis of prostate tissues prior to treatment with neoadjuvant ADT plus enzalutamide

Project description:Bulk Affymetrix Exon array analysis of prostate tissues prior to treatment with neoadjuvant ADT plus enzalutamide

| PRJNA759231 | ENA

Prostate Cancer Gene Expression Changes with Neoadjuvant Hormone Therapy

Project description:Men with clinically localized prostate cancer were treated with 0 to 9 months of neoadjuvant hormone suppression prior to prostatectomy. Keywords: microarray, hormone, 9 men with prostate cancer were assigned to neoadjuvant hormone suppression therapy for 3-6, 6, or 0 months.

2008-12-01 | E-GEOD-9983 | biostudies-arrayexpress

Novel Race-specific Genetic and Epigenetic Determinants of ADT-Resistance in African American Prostate Cancer

Project description:Purpose: The goals of this study is to compare NGS-derived Androgen Deprivation Therapy (ADT) resistant miRNome profiling to Androgen Deprivation Therapy (ADT) sensitive miRNome profile in African American prostate cancer cells and validate by reverse transcription polymerase chain reaction (qRT–PCR) methods. Method: Mirco-RNA were isolated from different CaP cells who were sensitive and resistant to Androgen Deprivation Therapy (ADT). Total micro-RNA were subjected to miRNA-Seq. Results: We performed whole miRNA-Seq analysis through paired-end deep sequencing to systematically investigate the molecular features of different CaP cell models- RC-77-N, RC-77T/E, RCC7T/E-ADT, RCC7T/E-CD133-plus, E006AA-hT and E006AA-hT-ADT. Conclusions: Our study represents the first detailed analysis of African American ADT resistant miRNome, with biologic replicates, generated by miRNA-seq technology.

2019-07-09 | GSE116636 | GEO

miRNAs expression of prostate cancer with neoadjuvant hormonal therapy

Project description:The aim of this research was to identify miRNAs that are associated with neoadjuvant hormonal therapy resisitance in prostate cancer.

2022-11-01 | GSE186994 | GEO

Prostate Cancer Gene Expression Changes with Neoadjuvant Hormone Therapy

Project description:Men with clinically localized prostate cancer were treated with 0 to 9 months of neoadjuvant hormone suppression prior to prostatectomy. Keywords: microarray, hormone,

2008-12-01 | GSE9983 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data